Listening to patients has been at the heart of our research efforts since our company’s inception. We have been determined to respond to the needs of children with severe and highly treatment-resistant forms of epilepsy, and has focused our efforts on the development of Epidiolex® (cannabidiol or CBD) as a potential new treatment option to address this important medical need.
Maintaining our focus on the potential benefit to patients has been a consistent driving force in our research program and progress to date. We are in a unique position to develop and manufacture consistent cannabinoid formulations worldwide at sufficient quality, uniformity and scale to meet international regulatory requirements.
There are a number of organizations which provide invaluable help, information, and support to people living with epilepsy. They are also a useful resource for caregivers, friends, and relatives. The following list includes links to some websites of patient organizations that may be useful.
- Epilepsy Foundation
- Dravet Syndrome Foundation
- Lennox-Gastaut Syndrome Foundation
- Tuberous Sclerosis Alliance
- Child Neurology Foundation
We are committed to respecting the primary role of healthcare providers in the treatment of epilepsy disorders. Therefore, we cannot respond to medical questions about your personal health situation, nor can we accept private medical information. Please contact your healthcare provider with any questions pertaining to your or a family member's medical condition.
If you are interested in participating in one of our sponsored clinical trials, please have your physician contact us by clicking here. For US medical inquires relating to Epidiolex® (CBD), please email us here or call 1-877-886-2810.
Epidiolex (CBD) is an investigational drug not approved for any indication.